Organogenesis CCO exercises options for 958 shares

Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.

Insider Trade Summary

958 shares exercised/converted

Exercise 2 txns

Insider Grow Brian

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	958	$0.00	$0.00
Exercise	Class A Common Stock	958	$1.24	$1K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Class A Common Stock — 900,682 shares (Direct)

Footnotes (1)

F1. 100% of the shares subject to the option are fully vested and exercisable.

Key Figures

Shares acquired via option exercise: 958 shares Exercise price: $1.24 per share Shares held after transaction: 900,682 shares +2 more

5 metrics

Shares acquired via option exercise 958 shares Class A Common Stock acquired on January 10, 2025

Exercise price $1.24 per share Conversion or exercise price of stock option

Shares held after transaction 900,682 shares Total direct Class A Common Stock after exercise

Option shares exercised 958 shares Stock Option (Right to Buy) underlying shares

Option expiration date January 12, 2025 Expiration date of the exercised stock option

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, Class A Common Stock, Form 4

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Organogenesis (ORGO) report for Brian Grow?

Brian Grow exercised stock options to acquire 958 shares of Organogenesis Class A Common Stock at $1.24 per share. This Form 4 shows a routine option exercise, increasing his directly held stake without any open-market buying or selling.

How many Organogenesis (ORGO) shares does Brian Grow hold after this filing?

After the reported option exercise, Brian Grow directly holds 900,682 shares of Organogenesis Class A Common Stock. The exercised option covered 958 shares, and that option position is now fully used with no remaining shares under that specific grant.

What was the exercise price of Brian Grow’s Organogenesis (ORGO) stock option?

The exercised stock option had a conversion or exercise price of $1.24 per share for 958 underlying shares. Exercising at this price converted the derivative position into common stock, as reflected in the Form 4’s non-derivative and derivative transaction entries.

Did Brian Grow sell any Organogenesis (ORGO) shares in this Form 4?

No sale is reported in this Form 4. The transactions are coded “M” for an option exercise, indicating conversion of a derivative into common stock. The summary data show acquire-side activity only, with no open-market selling or tax-withholding dispositions disclosed.

What does the footnote on Brian Grow’s Organogenesis (ORGO) option say?

The footnote states that 100% of the shares subject to the option are fully vested and exercisable. This means all 958 option shares were already earned under the plan and could be exercised, consistent with the reported derivative conversion on the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/24/2026 - 09:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grow Brian

(Last)

(First)

(Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON

MASSACHUSETTS

02021

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	01/10/2025		M		958	A	$1.24	900,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.24	01/10/2025		M			958	⁽¹⁾	01/12/2025	Class A Common Stock	958	$0	0	D

Explanation of Responses:

1. 100% of the shares subject to the option are fully vested and exercisable.

	/s/ William R. Kolb, Attorney-in-Fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR